Just reported in formal 8k filing by PURE:
The owner of Subway, the largest food chain in the world, through Franchise Brands, LLC, just invested $4million in PURE Bioscience as a strategic investment. This strongly implies that some very large restaurant chains will soon start buying “SDC” in very large quantities. Do you think it might be the 45,000 restaurant Subway?
Several other major QSR’s are likely to follow soon.
PURE is very STRONG BUY because they have almost $8 million in cash, the biggest breakthrough in food safety in decades using biotechnology, and revenues that are about to explode.
Sentiment: Strong Buy
Type “MicroCapReview” into your browser to learn why Millennium HealthCare (MHCC) stock price is about to explode and keep going for years. Click on “Read the latest issue and turn to page 22.
Sentiment: Strong Buy
Is it my turn this time to be holding this stock? All alone?
Hhheelll-llloooo....helllooooo! Is there anybody in there?
"Just nod if you can hear me"
"Is anyone home at all"
Should I rel-axxxxx. relaxx, relax.......just because its a little pin #$%$ of a Chemokine?
Bought some today @ 5.01+. Hard to find any bargains out there. This looks like a good one with a nice cash hoard to boot.
Picked this out of the cc transcript which is all I really need to hear.
"We remain highly focused on strategic partnering opportunities and hope to be able to share news on this front in the upcoming months."
Partnership. CCR9. They have interest. Data is presented in "meetings this fall" IMO they are ready. They are going to go with maintenance of remission in Crohn's disease which was untested in Phase-III with verirnon but hit good numbers in Phase-IIB in the PROTECT1. Possibly will tack on ulcerative colitis (huge) as it dove tails from approved momentum on Vedolizumab.
Step three of the Europe CLEAR...."we’ll have a much better handle on that in the coming weeks and we will be talking about that pretty soon"
Notice he says "coming months" Not late Q4...not next year. And they are splitting the data from SHIELD-1 by GSK and then comparing it to PROTECT-1 in house. Its going to be apples and oranges because GSK selected the wrong sample group.
Immuno-oncology program is getting some unexpected traction. I like it.
Two newer indications for 168, aHUS and IgA nephropathy, and its so good they are going to start trials in those indications "by the end" of this year.
Lastly, 872 is now a wild card as monocytic myeloid derived suppressor cells can't stand it so that opens the gates to pancreatic and breast cancer....they are tossing in Melanoma as well.
IMO if they hit on any of these its going to go ballistic. ICPT and other companies have done very well over the last few months by targeting and cornering strong results for obscure diseases (lupus nephritis). We are still early to the game here and its going to play out over the next 3 quarters.
Cowen, Stifel (currently not covering CCXI ???) and JP Morgan represneted. Goldman jumped in and an analyst from CITI had some interest. Adam Feuerstein and Yaron Werber have some interesting history.
Navdeep, Yaron and Geoff all have holds on CCXI at this point........Hmmmmmm..
Market is clearing out of stocks like CCXI. Its a great co with a great team, they just are not going to do anything significant for a year....or two. So its dead money and will just drift down as more and more people get tired of watching.
$4.85 - $4.95 has always been key support and should hold up fine just like it always does.
Revenues driven by recent contracts for the most advanced life saving diagnostics will expand 150 times in the next 24 months. And that is just the beginning!
Millennium Healthcare (MHCC) recently announced newly SIGNED contracts with ACO’s IPA’s and MSO’s to provide exclusive, state-of-the-art, non-invasive cardiovascular and cancer diagnostics to 1,300 locations that will escalate Millennium’s current revenues of $2 million per year to over $300 million per year.
Cardiovascular and cancer diagnostics rolling out to physician’s offices this year.
Revenues will begin rapid growth by year end.
Market size for Millennium Diagnostics is 35,000 primary care offices. The first 1,300 recently contracted with Millennium and the rest are standing in line to sign up with Millennium because:
§ Millenniums program increases physician’s revenues dramatically
§ Millennium’s diagnostics are fully paid by Medicare and are free to patients
§ Millennium’s diagnostics appeal to patients because they are life-saving, fast, painless and highly accurate
§ Millennium’s diagnostics are exclusive from Millennium only
§ The physician pays no up front capital costs
Millennium’s market cap is under $40 million today and shares are selling at under $1.00.
What will this growth do to the price of MHCC shares?
Millennium HealthCare is well positioned for explosive growth that is rarely seen.
Sentiment: Strong Buy
Check out AFFY price action today. Directors basically tossed in the towel and decided to call it quits and fold up. Cease operations as they were getting nowhere. They totally got destroyed on some bad data and then it was a long slow glide down.
Call me suspicious, but the recent high profile hire CCXI brought on was none other than Anne-Marie S. Duliege, M.D., M.S. She was a part of that disaster but got out before it did its slide from $27.00 to 0.11 cents.
I'll say that again. AFFY went from $27.00 per share to 11 cents and the executives got paid all along.
I sure as heck hope she wasn't brought on board based on what she did over there and that CCXI is hoping for a very very different outcome.
I'm beginning to grow tired of biotechs......
Can't post the link here, but this came up on my feed today. Its from an article in Japan, referencing the source as both ChemoCentryx and AMGEN.
Modulation of CCR4 function
US 7262204 B2
Any thoughts out there on what a "short list" might be for potential new partners going forward? I wonder too if GSK takes a second look now.